Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality

Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy subjects to determine the absorption, distribution, metabolism, and excretion of pexidartinib using radiolabeled...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahir, Hamim, Greenberg, Jonathan, Hsu, Ching, Watanabe, Kengo, Makino, Chie, He, Ling, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099993/
https://www.ncbi.nlm.nih.gov/pubmed/36369799
http://dx.doi.org/10.1002/cpdd.1186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099993/
https://www.ncbi.nlm.nih.gov/pubmed/36369799
http://dx.doi.org/10.1002/cpdd.1186

Ejemplares similares